Related Experiment Video

Updated: Mar 8, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K

The nucleoside analog clitocine is a potent and efficacious readthrough agent

Westley J Friesen1, Christopher R Trotta2, Yuki Tomizawa2

  • 1PTC Therapeutics, Inc., South Plainfield, New Jersey 07080, USA wfriesen@ptcbio.com.

RNA (New York, N.Y.)
|January 19, 2017
PubMed

Insights

Clitocine, a nucleoside analog, effectively suppresses nonsense mutations by inducing premature stop codon readthrough. This novel therapeutic approach restores functional protein production, offering a new treatment for cancers and genetic diseases.

Area of Science:

  • Molecular Biology
  • Genetics
  • Pharmacology

Background:

  • Nonsense mutations in tumor suppressor genes are prevalent in many cancers.
  • These mutations lead to premature stop codons, contributing to disease progression.
  • Readthrough-inducing compounds offer a potential therapeutic strategy.

Purpose of the Study:

  • To identify and characterize compounds that can induce readthrough of nonsense mutations.
  • To evaluate the therapeutic potential of clitocine in cancer treatment.

Main Methods:

  • Identified clitocine as a nucleoside analog with nonsense mutation readthrough activity.
  • Investigated clitocine's mechanism of action, focusing on RNA incorporation.
  • Assessed clitocine's ability to restore p53 protein production and function in cancer cells.
  • Evaluated clitocine's efficacy in xenograft tumor models of ovarian cancer.

Main Results:

  • Clitocine incorporation into RNA during transcription is essential for readthrough.
  • Clitocine directly induces readthrough when present in the third position of a premature stop codon.
  • Clitocine restored full-length, functional p53 protein in cells with p53 nonsense mutations.
  • This restoration led to transcriptional activation, apoptosis, and impeded tumor growth in vivo.

Conclusions:

  • Clitocine represents a novel therapeutic agent for genetic disorders and cancers caused by nonsense mutations.
  • It acts through a previously undescribed mechanism to induce nonsense mutation readthrough.
  • Clitocine holds promise as a new treatment modality for various diseases.
Keywords:
clitocinenonsense suppressionnucleoside analogp53 therapyreadthroughstop codon

More Related Videos

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors08:33

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors

Published on: January 19, 2015

9.3K
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.3K

Related Concept Videos

Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
703
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
15.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
701
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
755